Literature DB >> 21516133

Metabolic and pharmacokinetic studies of scutellarin in rat plasma, urine, and feces.

Jian-feng Xing1, Hai-sheng You, Ya-lin Dong, Jun Lu, Si-ying Chen, Hui-fang Zhu, Qian Dong, Mao-yi Wang, Wei-hua Dong.   

Abstract

AIM: To study the metabolic and pharmacokinetic profile of scutellarin, an active component from the medical plant Erigeron breviscapus (Vant) Hand-Mazz, and to investigate the mechanisms underlying the low bioavailability of scutellarin though oral or intravenous administration in rats.
METHODS: HPLC method was developed for simultaneous detection of scutellarin and scutellarein (the aglycone of scutellarin) in rat plasma, urine and feces. The in vitro metabolic stability study was carried out in rat liver microsomes from different genders.
RESULTS: After a single oral dose of scutellarin (400 mg/kg), the plasma concentrations of scutellarin and scutellarein in female rats were significantly higher than in male ones. Between the female and male rats, significant differences in AUC, t(max2) and C(max2) for scutellarin were found. The pharmacokinetic parameters of scutellarin in the urine also showed significant gender differences. After a single oral dose of scutellarin (400 mg/kg), the total percentage excretion of scutellarein in male and female rats was 16.5% and 8.61%, respectively. The total percentage excretion of scutellarin and scutellarein in the feces was higher with oral administration than with intravenous administration. The in vitro t(1/2) and CL(int) value for scutellarin in male rats was significantly higher than that in female rats.
CONCLUSION: The results suggest that a large amount of ingested scutellarin was metabolized into scutellarein in the gastrointestinal tract and then excreted with the feces, leading to the extremely low oral bioavailability of scutellarin. The gender differences of pharmacokinetic parameters of scutellarin and scutellarein are due to the higher CL(int) and lower absorption in male rats.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516133      PMCID: PMC4002508          DOI: 10.1038/aps.2011.11

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  25 in total

1.  Gender-based differences in rats after chronic dietary exposure to genistein.

Authors:  W Slikker; A C Scallet; D R Doerge; S A Ferguson
Journal:  Int J Toxicol       Date:  2001 May-Jun       Impact factor: 2.032

2.  Stability of baicalin in biological fluids in vitro.

Authors:  Jie Xing; Xiaoyan Chen; Dafang Zhong
Journal:  J Pharm Biomed Anal       Date:  2005-09-15       Impact factor: 3.935

3.  Study on the role of hepatic first-pass elimination in the low oral bioavailability of scutellarin in rats.

Authors:  Xinhua Hao; Gang Cheng; J E Yu; Yungxia He; Feng An; Jin Sun; Fude Cui
Journal:  Pharmazie       Date:  2005-06       Impact factor: 1.267

4.  Determination of aglycone conjugated metabolites of scutellarin in rat plasma by HPLC.

Authors:  Jianming Huang; Ni Li; Yunqiu Yu; Weiyu Weng; Xubing Huang
Journal:  J Pharm Biomed Anal       Date:  2005-09-21       Impact factor: 3.935

5.  Pharmacokinetics of scutellarin and its aglycone conjugated metabolites in rats.

Authors:  J M Huang; W Y Weng; X B Huang; Y H Ji; E Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

6.  Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration.

Authors:  Xiaoyan Chen; Liang Cui; Xiaotao Duan; Bin Ma; Dafang Zhong
Journal:  Drug Metab Dispos       Date:  2006-05-19       Impact factor: 3.922

7.  The anti-HIV-1 effect of scutellarin.

Authors:  Gao-Hong Zhang; Qian Wang; Ji-Jun Chen; Xue-Mei Zhang; Siu-Cheung Tam; Yong-Tang Zheng
Journal:  Biochem Biophys Res Commun       Date:  2005-09-02       Impact factor: 3.575

8.  Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways.

Authors:  Zhen-Wei Pan; Ying Zhang; Dong-Hua Mei; Rui Zhang; Jing-Hao Wang; Xiang-Ying Zhang; Chang-Qing Xu; Yan-Jie Lu; Bao-Feng Yang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-06       Impact factor: 3.000

9.  Effect of new-breviscapine on fibrinolysis and anticoagulation of human vascular endothelial cells.

Authors:  Q S Zhou; Y M Zhao; X Bai; P X Li; C G Ruan
Journal:  Zhongguo Yao Li Xue Bao       Date:  1992-05

10.  Differential effects of new breviscapine on arachidonic acid metabolisms in blood cells and endothelial cells.

Authors:  Z Y Wang; D C Chen; Y He; C G Ruan; R W Zhang
Journal:  Zhongguo Yao Li Xue Bao       Date:  1993-03
View more
  5 in total

1.  Scutellarein protects against cardiac hypertrophy via suppressing TRAF2/NF-κB signaling pathway.

Authors:  Xiujuan Shi; Yongjia Hu; Yuxiong Jiang; Jiawen Wu; Chen Zhang; Jieping Zhang; Shengyu Wu; Yingshi Wu; Weibing Dong; Jue Li
Journal:  Mol Biol Rep       Date:  2022-01-06       Impact factor: 2.316

2.  Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle.

Authors:  Vivian Chen; Richard E Staub; Scott Baggett; Ramesh Chimmani; Mary Tagliaferri; Isaac Cohen; Emma Shtivelman
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

Review 3.  New Insights toward Colorectal Cancer Chemotherapy Using Natural Bioactive Compounds.

Authors:  Saúl Redondo-Blanco; Javier Fernández; Ignacio Gutiérrez-Del-Río; Claudio J Villar; Felipe Lombó
Journal:  Front Pharmacol       Date:  2017-03-14       Impact factor: 5.810

4.  Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.

Authors:  Jingnan Wang; Jiayun Tan; Jiahao Luo; Peilin Huang; Wuyi Zhou; Luming Chen; Lingli Long; Li-Ming Zhang; Banghao Zhu; Liqun Yang; David Y B Deng
Journal:  J Nanobiotechnology       Date:  2017-03-01       Impact factor: 10.435

5.  Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.

Authors:  Xinran Wang; Cai Zhang; Ning Han; Juyuan Luo; Shuofeng Zhang; Chunguo Wang; Zhanhong Jia; Shouying Du
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.